Adaptive Biotechnologies Announces \$250 Million Convertible Senior Notes Offering, Strategic Use of Proceeds, and Share Repurchase Plan
Key Highlights
- Proposed Offering: Adaptive Biotechnologies (Nasdaq: ADPT) intends to offer \$250 million aggregate principal amount of convertible senior notes due 2031 in a private placement to qualified institutional buyers.
- Optional Additional Notes: Initial purchasers are expected to have an option to buy up to an additional \$37.5 million of notes within 13 days of issuance.
- Primary Use of Proceeds: Proceeds will be used to repay the OrbiMed Purchase Agreement, fund capped call transactions, repurchase up to \$25 million of common stock, and for general corporate purposes and opportunistic MRD business initiatives.
- Potential Shareholder Impact: The company plans to repurchase its own shares to reduce potential dilution, which may support or increase the stock price during the offering period.
- Capped Call Transactions: These are designed to reduce dilution upon conversion of notes and/or offset potential cash payments above the principal amount if notes are converted.
- JWCA Purchase: J. Wood Capital Advisors LLC, the company’s financial advisor, intends to purchase up to \$10 million of the company’s stock concurrently with the offering.
- Conversion and Redemption Terms: Notes are convertible into cash, stock, or a mix at the company’s discretion. Redemption is possible after July 1, 2029, if certain price conditions are met.
- Potential Price Sensitivity: These actions may result in higher trading prices for the company’s stock, a higher initial conversion price for the notes, and may influence share price volatility.
- Forward-Looking Statements: The company notes risks such as market conditions and volatility, the ability to complete the offering, and application of proceeds as intended.
Detailed Article for Investors
Seattle, June 15, 2026 – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis and treatment, has announced a major financial initiative. The company intends to raise \$250 million through the issuance of convertible senior notes due 2031, with an option for initial purchasers to acquire an additional \$37.5 million in notes. This private offering is directed towards qualified institutional buyers under Rule 144A of the Securities Act.
Strategic Use of Proceeds
- Repayment of OrbiMed Purchase Agreement: The company aims to utilize a significant portion of the net proceeds to repay its obligations under the OrbiMed Purchase Agreement, enhancing its financial flexibility.
- Capped Call Transactions: A portion of the proceeds will fund capped call transactions with one or more financial institutions. These derivative transactions are intended to mitigate dilution upon conversion of the notes and potentially reduce cash outlays above the principal amount if notes are converted.
- Share Repurchase: Up to \$25 million of the proceeds will be used to buy back shares of the company’s common stock in privately negotiated transactions. This concurrent repurchase is expected to reduce share dilution and may support the company’s stock price during the offer period.
- General Corporate Purposes and MRD Initiatives: Remaining funds are earmarked for general use and strategic opportunities in the company’s Minimal Residual Disease (MRD) business segment.
Convertible Notes Terms and Shareholder Implications
- Interest and Maturity: The notes are unsecured senior obligations, with interest payable semi-annually, maturing on July 1, 2031, unless earlier converted, redeemed, or repurchased.
- Conversion Features: Holders may convert their notes under certain conditions, with the company having flexibility to settle conversions in cash, stock, or a mix of both.
- Redemption Provisions: Adaptive Biotechnologies can redeem the notes in whole or in part for cash after July 1, 2029, if the stock price exceeds 130% of the conversion price for a certain period. Notes may also be redeemed in full if less than 15% of the original aggregate principal remains outstanding.
- Impact of Repurchases and Hedging: The company’s share repurchases and the hedging activity by capped call counterparties and JWCA may cause or prevent movements in both the stock and note prices, potentially making the shares more attractive during the offering period and impacting the effective conversion price for the notes.
- Unregistered Securities: The notes and any shares issuable upon conversion are not registered under the Securities Act and may only be sold in transactions exempt from or not subject to registration requirements.
Company Overview and Outlook
Adaptive Biotechnologies is a leader in immune medicine, using a proprietary platform to decode the genetics of the adaptive immune system. This platform supports drug development and clinical diagnostics, with commercial and pipeline offerings in both MRD and immune medicine segments. The company’s goal is to deliver personalized, immune-driven therapies and diagnostics for diseases such as cancer and autoimmune disorders.
Forward-Looking Statements and Risks
The company cautions that the offering is subject to market conditions and other risks, including the volatility of its share price. There is no assurance the offering will be completed as planned or that proceeds will be used as intended. Investors are encouraged to review the company’s SEC filings for additional risk factors.
Important Information for Shareholders
- The proposed issuance and repurchase plan could be price-sensitive, with the potential to move the share price both due to the buyback program and possible dilution from future note conversions.
- The capped call transactions are a significant measure to protect against dilution but are only effective up to a set “cap” price. If the share price exceeds this cap, further dilution could occur.
- The involvement of JWCA in purchasing shares and the hedging activities around the capped call transactions could increase trading activity and volatility in the stock.
- Investors should closely monitor further announcements regarding the final terms and completion of the offering, as well as any shifts in the company’s capital structure or strategic initiatives resulting from these transactions.
Contact Information
- Investor Relations: Karina Calzadilla – 201-396-1687, [email protected]
- Media: Erica Jones – 206-279-2423, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should consult their own advisors and review official company filings before making any investment decisions. The information herein reflects the company’s public disclosures as of the date of the announcement and may be subject to change without notice.
